콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

A-008

Supelco

S(+)-Amphetamine (dextro-Amphetamine) solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

동의어(들):

dextro-Amphetamine

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C9H13N
CAS Number:
51-64-9
Molecular Weight:
135.21
MDL number:
MFCD00133300
UNSPSC 코드:
41116107
PubChem Substance ID:
329770571
NACRES:
NA.24

Grade

certified reference material

Quality Level

300

양식

liquid

특징

SNAP-N-SPIKE®. SNAP-N-SHOOT®

포장

ampule of 1 mL

제조업체/상표

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

농도

1.0 mg/mL in methanol

기술

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

응용 분야

forensics and toxicology

형식

single component solution

저장 온도

−20°C

SMILES string

C[C@H](N)Cc1ccccc1

InChI

1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

InChI key

KWTSXDURSIMDCE-QMMMGPOBSA-N

유전자 정보

human ... SLC18A2(6571)

관련 카테고리

일반 설명

Amphetamine is a stimulant of the phenethylamine class found in ADHD-treatment drugs such as Adderall®, Vyvanse®, and ProCentra®. Because of its stimulant effect, amphetamine is used recreationally as a performance-enhancer and illicit drug. This Certified Snap-N-Spike® Solution is suitable for use in urine drug testing, clinical toxicology, forensic analysis, and isomer identification by LC-MS/MS or GC/MS.

법적 정보

Adderall is a registered trademark of Richwood Pharmaceutical Company, Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
ProCentra is a registered trademark of Outlook Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vyvanse is a registered trademark of Shire, LLC

관련 제품

제품 번호
설명
가격

A-016

(±)-Amphetamine-d11 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-050

Amine Mixture-6 solution, 250 μg/mL each component in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-002

(±)-Amphetamine-d5 (deuterium label on ring) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-005

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-007

(±)-Amphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-013

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-017

(±)-Amphetamine-d8 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-018

(±)-Amphetamine-d8 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-019

(±)-Amphetamine-d11 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-044

(±)-Amphetamine-d6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-045

(±)-Amphetamine-d6 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-049

R(-)-Amphetamine (levo-Amphetamine), 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

E-018

(±)-N-Ethylamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-026

Lisdexamfetamine dimesylate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

L-028

Lisdexamfetamine-D4 dimesylate solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

P-050

PMA hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

A-212

(±)-Amphetamine-13C6 hydrochloride solution, 100 μg/mL in methanol ((as free base)), certified reference material, ampule of 1 mL, Cerilliant®

픽토그램

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

신호어

Danger

유해 및 위험 성명서

H225,H301 + H311 + H331,H370

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

표적 기관

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point (°F)

49.5 °F - closed cup

Flash Point (°C)

9.7 °C - closed cup

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

J H Check et al.
Clinical and experimental obstetrics & gynecology, 40(2), 227-228 (2013-08-27)
To further investigate the efficacy of treatment of interstitial cystitis that had been refractory to standard treatment with sympathomimetic amines. Dextroamphetamine sulfate sustained release capsules up to 30 mg per day were prescribed in women with refractory painful bladder syndrome/interstitial
Sanders A McDougall et al.
Pharmacology, biochemistry, and behavior, 104, 154-162 (2013-01-31)
The early ontogeny of D-amphetamine-induced one-trial behavioral sensitization was characterized using male and female preweanling and preadolescent rats. In Experiment 1, rats were injected with saline or D-amphetamine (1, 4, or 8mg/kg) in activity chambers or the home cage on
J H Check et al.
Clinical and experimental obstetrics & gynecology, 40(2), 284-285 (2013-08-27)
Sympathetic nervous system hypofunction has been found to be associated with motility disorders of the bowel, including gastroparesis, pseudointestinal obstruction, and esophageal motility disorders. These disorders respond to sympathomimetic amine therapy. The purpose of this study was to see if
Greg W Mattingly et al.
BMC psychiatry, 13, 39-39 (2013-01-30)
Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of
Joel L Young
Postgraduate medicine, 125(1), 162-168 (2013-02-09)
Fatigue is commonly reported in the primary care setting; however, its cause is often unclear. This article presents 3 cases involving patients with chronic fatigue syndrome who responded poorly to treatment. After clinical evaluation, all patients were found to meet
모든 관련된 서류 보기

문서

LC/MS Analysis of Amphetamine Enantiomers on Astec CHIROBIOTIC® V2 in Urine after Solid Phase Extraction (SPE) using Supel™-Select SCX

Shown here is the chiral separation of amphetamine enantiomers under MS-compatible conditions on Astec CHIROBIOTIC® V2 after extraction from urine using Supel™-Select SCX SPE 96-well plates. The highest grade mobile phase solvents and additives were used to supply low background interference and low particulate contaminants for robust, trouble-free operation. Cerilliant CRMs provided reliable identification and quantification.

프로토콜

Accurate Biological Testing for Amphetamine and Methamphetamine Abuse Using Chiral HPLC and MS Detection

Optimized sample prep and chiral chromatography methods for the LC/MS analysis of these drug enantiomers in urine

Biological Testing for Amphetamine and Methamphetamine Abuse

In this study, optimized methods are presented for sample preparation and chiral chromatography for the LC/MS analysis of amphetamine and methamphetamine enantiomers in urine.

Global Trade Item Number

SKUGTIN
SML2705-5MG4065265792714
SML2705-25MG4065265792707
HGPVS0KIT
YY3000392
LSVNTVALS
YY3000394
A-008-1ML4061837816499

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.